¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2024 Spring Semi-Annual Meeting (2ÀÏÂ÷) : 2024-05-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2024 Spring Semi-Annual Meeting (2ÀÏÂ÷) : 2024-05-11
±³À°ÀÏÀÚ : 2024-05-11
±³À°Àå¼Ò : ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ

±³À°ÁÖÁ¦ : KGOG 2024 Spring Semi-Annual Meeting (2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸

´ã´çÀÚ : ±èÇý¼÷
¿¬¶ôó : 02-512-5420

À̸ÞÀÏ : kelly.kim1436@gmail.com

±³À°Á¾·ù : »êºÎÀΰú

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : °æ±âµµ
±³À°½Ã°£ : 7 ½Ã°£ 37ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í KGOG : Korean Gynecologic Oncology Group »ç´Ü¹ýÀÎ ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ ¾àÀÚÀÔ´Ï´Ù.*ÇÁ·Î±×·¥¿¡ KGOG·Î µÇ¾îÀÖ´Â ºÎºÐ Âü°í ºÎŹµå¸³´Ï´Ù.


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 09:00~09:15 The Role and Utilization of Biobanks: a Key to the Translational Research and Drug Development ½ÅÀº¾Æ(¿ëÀμ¼ºê¶õ½ºº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 09:15~09:30 Global Biobank Landscape and Operations: Insights from NCI (NRG, SWOG), ENGOT, and GOG-F ±Çº´¼ö(°æÈñÀÇ·á¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 09:30~09:45 Application of bioinformatics to investigate cancer etiology and provide clinical implications: analyzing large-scale, multi-dimensional data including biobank sources. ÀÌ¿ì¾ß(National Institutes of Health)

Åä·Ð 05¿ù 11ÀÏ Room A 09:45~09:50 Discussion ÇÑ°üÈñ, Ȳ¿ì¿¬(»ó°è¹éº´¿ø, °æÈñ´ëº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room B 09:00~09:15 Up-to-date Management & Guideline status for Endometrial cancer patients ±è¹Î±Ô(»ï¼ºÃ¢¿øº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room B 09:15~09:30 KGOG2035/NRG-GY026 ¡°A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA¡± ÀÌÀº¼±(´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸)

±³À°½Ã°£ 05¿ù 11ÀÏ Room B 09:30~09:45 KGOG3067/SOCCER-P ¡°A Randomized Phase II Study of Secondary Cytoreductive Surgery in Patients with Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance¡± ±è¹Î¼­(´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸)

Åä·Ð 05¿ù 11ÀÏ Room B 09:45~09:50 Discussion ()

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:00~10:03 1. Intorduction/Review of ongoing study (ÀÚÀ¯) ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:03~10:10 KGOG 3051/NRG-GY019 : A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum (ÀÚÀ¯) ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:10~10:17 KGOG 3053/NRG-CC008 clinical trial : A Non-Randomized Prospective Clinical Trail Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROC) (ÀÚÀ¯) ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:17~10:24 KGOG 3055/JGOG 3024 : Biobank cohort study in subjects who have not developed ovarian cancer to determine BRCA1/2 gene variants and the incidence, clinicopathological characteristics, and risk factors in the development of cancer (ÀÚÀ¯) ÀÌÁ¤¿ø(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:24~10:31 KGOG 3059 : A cohort study to assess the safety and efficacy of PARP inhibitor maintenance after first-line therapy of Korean women with advanced ovarian/fallopian/peritoneal cancer (ÀÚÀ¯) ÀÌÀºÁÖ(Á߾Ӵ뺴¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:31~10:38 KGOG 3064/KROG 2204 : Prospective Multi-institutional Phase III Trial of Salvage Systemic Therapy with or without Stereotactic ABl ative Radiation Therapy for Recurrent Ovarian Cancer (ÀÚÀ¯) ±è¿ë¹è(¿¬¼¼¾Ïº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:38~10:45 KGOG 3067 : A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance (SOCCER-P) (ÀÚÀ¯) Á¶Çö¿õ(°í´ë±¸·Îº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:45~10:55 Closed study : presentation    Phase II trial evaluating the Efficacy and safety of physician chosen chemotherapy with hormonaL therapy in patientS with heavily pretreated Advanced epithelial ovarian, fallopian tube or primary peritoneal cancer: A multicenter pilot study (ELSA) (ÀÚÀ¯) À̹æÇö(ÀÎÇϴ뺴¿ø)

ÈÞ½Ä 05¿ù 11ÀÏ Lobby 11:00~11:15 Coffee Break ()

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:15~11:20 Cervix, Vulva, Vagina Committee : List of ongoing KGOG trials (ÀÚÀ¯) Á¤¿ë¿í(°­³²Â÷º´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:20~11:24 Featuring KGOG protocol: 1. completed protocol : SELPAX (ÀÚÀ¯) ±è¹®È«(¿øÀڷº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:24~11:28 Featuring KGOG protocol: 2. ongoing protocol : AFTER (ÀÚÀ¯) ½É½ÂÇõ(°Ç±¹´ëº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:28~11:32 Featuring KGOG protocol: 3. new protocol : CRASH (ÀÚÀ¯) ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:32~11:42 Overview of recent trials with different setting: 1.early cervical cancer: SHAPE, ConCerv, SENTIX (ÀÚÀ¯) À̼±¹Ì(°í´ë¾È¾Ïº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:42~11:52 Overview of recent trials with different setting: 2. locally advanced cancer: INTERLACE, KNA18, (ÀÚÀ¯) ±èÁ¤Ã¶(¼øõÇâ´ëºÎõº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:52~12:02 Overview of recent trials with different setting: 3. Advanced/ Metastatic cancer : BEATcc, KN826 (ÀÚÀ¯) ÀÌÁöÇö(ÀÏ»êÂ÷º´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 12:02~12:12 Overview of recent trials with different setting: 4. 2nd line therapy : EMPOWER, InnovaTV301 (ÀÚÀ¯) ¼ÛÈñ°æ(ÀÎõ¼º¸ðº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 12:15~12:35 Sustained benefit of olaparib in BRCAm patients with newly diagnosed ovarian cancer. ¹é¹ÎÇö(°­¿ø´ëÇб³º´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 12:35~12:55 How to manage adverse events and dose modification for PARP inhibitors in ovarian cancer. ¼³¾Ö¶õ(°í´ë¾È»êº´¿ø)

Åä·Ð 05¿ù 11ÀÏ Room A 12:55~13:05 Discussion ¿À¿µÅÃ(°í´ë¾È»êº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room B 12:15~12:55 New era of treatment in Endometrial cancer: Unmet needs and Look to the future ¼Û¿ëÁß(ºÎ»ê´ëº´¿ø)

Åä·Ð 05¿ù 11ÀÏ Room B 12:55~13:05 Discussion ¾î°æÁø(¿ëÀμ¼ºê¶õ½ºº´¿ø)

ÈÞ½Ä 05¿ù 11ÀÏ Lobby 13:15~13:30 Coffee Break ()

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 13:30~13:45 GOG-P/KGOG Session: Partnership Time Reporting between GOG-P & KGOG ¼ÛÀçÀ±(°í´ë¾È¾Ïº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 13:45~14:00 GOG-P/KGOG Session: Joint Papers for Intergroup Accord and SIT Á¤ÇöÈÆ(¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 14:00~14:15 GOG-P/KGOG Session: Current and Upcoming Studies of GOG-P/KGOG À̼ºÁ¾(¼­¿ï¼º¸ðº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 14:15~14:30 GOG-P/KGOG Session: Provisional KGOG-P for International SIT ±èº´±â(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 14:30~14:45 GOG-P/KGOG Session: Future Perspectives on Collaboration with GOG-P and Beyond ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø)

Åä·Ð 05¿ù 11ÀÏ Room A 14:45~14:55 Discussion ±è»ó¿î, ±è¹Î±Ô(¿¬¼¼¾Ïº´¿ø, »ï¼ºÃ¢¿øº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:00~15:10 Uterine Corpus-GTT Committee: KGOG Corpus Statistics Report till 2023 (ÀÚÀ¯) ±è¹Î±Ô(»ï¼ºÃ¢¿øº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:10~15:14 Review of ongoing study: 1. 2020  Fertility,1st-MPA (ÀÚÀ¯) ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:14~15:18 Review of ongoing study: 2. 2021  TREE PRO(no LN) (ÀÚÀ¯) ±è±âµ¿(ºÐ´ç¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:18~15:22 Review of ongoing study: 3. 2024  Re GTT,Keytruda (ÀÚÀ¯) ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:22~15:26 Review of ongoing study: 4. 2029  SELYE(Sentinel) (ÀÚÀ¯) ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:26~15:30 Review of ongoing study: 5. 2031  JGOG2051:Re-MPA (ÀÚÀ¯) ¿À¿µÅÃ(°í´ë¾È»êº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:30~15:34 Review of ongoing study: 6. 2034  ECLAT:ALL LN (ÀÚÀ¯) ±èÀç¿ø(¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:34~15:38 Review of ongoing study: 7. 2035  NRG GY026:1st-HER2 (ÀÚÀ¯) ±è¹Î±Ô(»ï¼ºÃ¢¿øº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:38~15:55 Uterine Corpus-GTT Committee : New Proposal ¹ÚÁ¤¿­(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:55~16:00 Closing ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2024 Spring Semi-Annual Meeting (2ÀÏÂ÷) : 2024-05-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ¼ºÇü¿Ü°úÇб³½Ç â¸³ 50Áֳ⠱â³ä Çмú´ëȸ : 2024-05-11
´ÙÀ½±Û 2024³â ´ëÇѺ´¸®ÇÐȸ º½Çмú´ëȸ(2ÀÏÂ÷) : 2024-05-10
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
422 ¼­¿ï Á߾Ӵ뺴¿ø È£Èí±â¾Ë·¹¸£±â³»°ú ¿¬¼ö°­Á : 2018-09-09 1 810 2018-08-15
421 ¼­¿ï ´ëÇѼºÇü¿Ü°úÇÐȸ Ç׳ëÈ­¼ºÇü¿¬±¸È¸ Á¦4ȸ ½ÉÆ÷Áö¾ö : 2018-09-09 0 824 2018-08-15
420 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦1ȸ ºñ¸¸Àü¹®°¡ ½ÉÈ­°úÁ¤: ºñ¸¸ Àü¹® ÀÎÁ¤ÀÇ ±³À° Part 1. : 2018-09-09 0 584 2018-08-15
419 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø 2018³â Çù·Âº´ÀÇ¿ø ÀÇ»ç ¿¬¼ö°­Á : 2018-09-09 0 1,366 2018-08-15
418 ¼­¿ï Á¦1ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ESD¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-08 0 875 2018-08-15
417 ¼­¿ï Á¦11ȸ ¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø ÁßȯÀÚÀÇÇÐ ¿¬¼ö°­Á Basic Concepts in Intensive Care, 2018 (BACIC 2018) : 2018-09-08 0 1,384 2018-08-15
416 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ °í·Á´ëÇб³ °í°üÀý ½ÉÆ÷Áö¿ò : 2018-09-08 0 1,108 2018-08-15
415 ¼­¿ï 2018 ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2018-09-08 0 522 2018-08-15
414 ºÎ»ê ´ëÇѼ¼Æ÷º´¸®ÇÐȸ International Session of the 30th Annual Fall Meeting of the Korean Society for Cytopathology : 2018-09-08 0 601 2018-08-15
413 ºÎ»ê 2018³â ºÎ¿ï°æ³»ºÐºñ´ë»çÇÐȸ ´ç´¢º´±³À°ÀÚ ¼¼¹Ì³ª : 2018-09-08 0 1,078 2018-08-15
412 ±¤ÁÖ Àü³²´ëº´¿ø Á¦ 3Â÷ Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç ¿¬¼ö°­Á : 2018-09-08 0 1,092 2018-08-15
411 ºÎ»ê ºÎ»ê´ëº´¿ø 2018³â Á¦1Â÷ ¸ð¹ß¿¬¼ö±³À° (ÁÖÁ¦: Å»¸ðÁõÀÇ Áø´Ü°ú Ä¡·á) : 2018-09-08 0 1,437 2018-08-15
410 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¦6ȸ ¾ÆÁÖ ´ç´¢¹ß ¹× â»ó ½ÉÆ÷Áö¾ö : 2018-09-08 0 1,217 2018-08-15
409 ±¤ÁÖ 2018 Àü³²´ëÇб³º´¿ø ÁßȯÀÚÀÇÇнÉÆ÷Áö¿ò ¹× ±â°èȯ±â¿öÅ©¼ó : 2018-09-08 0 742 2018-08-15
408 ¼­¿ï 2018 ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2018-09-07 0 469 2018-08-15
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷